U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Esophageal Adenocarcinoma

MedGen UID:
1779223
•Concept ID:
C5447503
•
Neoplastic Process

Definition

Esophageal adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Esophageal Adenocarcinoma

Professional guidelines

PubMed

Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Zhou C, Shangguan C, Shi M, Xi W, Wu J, Yang H, Guo L, Cai Q, Shi Y, Liu J, Zhang J
Future Oncol 2022 Jul;18(23):2495-2503. Epub 2022 Jun 15 doi: 10.2217/fon-2021-1579. PMID: 35703115
Advances in the treatment of gastric cancer.
Ilson DH
Curr Opin Gastroenterol 2017 Nov;33(6):473-476. doi: 10.1097/MOG.0000000000000395. PMID: 28877045
Current treatment options for esophageal diseases.
Martínek J, Akiyama JI, Vacková Z, Furnari M, Savarino E, Weijs TJ, Valitova E, van der Horst S, Ruurda JP, Goense L, Triadafilopoulos G
Ann N Y Acad Sci 2016 Oct;1381(1):139-151. Epub 2016 Jul 8 doi: 10.1111/nyas.13146. PMID: 27391867

Recent clinical studies

Etiology

Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS
Med Clin North Am 2023 May;107(3):491-504. Epub 2023 Feb 20 doi: 10.1016/j.mcna.2023.01.002. PMID: 37001949
Liver resection after Transjugular Portosystemic Stent Shunt (TIPSS).
Sliwinski S, Trojan J, Mader C, Vogl T, Bechstein W
Z Gastroenterol 2023 Apr;61(4):390-393. Epub 2022 Jun 13 doi: 10.1055/a-1791-2192. PMID: 35697061
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Minimally invasive esophagectomy for dysplastic Barrett's esophagus.
Markar SR, Hanna G
World J Surg 2015 Mar;39(3):608-14. doi: 10.1007/s00268-014-2746-1. PMID: 25145822
Management of refractory and complicated reflux esophagitis.
Hirschowitz BI
Yale J Biol Med 1996 May-Jun;69(3):271-81. PMID: 9165696Free PMC Article

Diagnosis

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J
Br J Cancer 2024 Feb;130(3):476-482. Epub 2023 Dec 22 doi: 10.1038/s41416-023-02534-1. PMID: 38135713Free PMC Article
Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS
Med Clin North Am 2023 May;107(3):491-504. Epub 2023 Feb 20 doi: 10.1016/j.mcna.2023.01.002. PMID: 37001949
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature.
Zhang C, Yu GM, Zhang M, Liu D
Medicine (Baltimore) 2020 Jan;99(1):e18691. doi: 10.1097/MD.0000000000018691. PMID: 31895837Free PMC Article
Minimally invasive esophagectomy for dysplastic Barrett's esophagus.
Markar SR, Hanna G
World J Surg 2015 Mar;39(3):608-14. doi: 10.1007/s00268-014-2746-1. PMID: 25145822
Management of refractory and complicated reflux esophagitis.
Hirschowitz BI
Yale J Biol Med 1996 May-Jun;69(3):271-81. PMID: 9165696Free PMC Article

Therapy

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J
Br J Cancer 2024 Feb;130(3):476-482. Epub 2023 Dec 22 doi: 10.1038/s41416-023-02534-1. PMID: 38135713Free PMC Article
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ
Ann Oncol 2021 Jun;32(6):746-756. Epub 2021 Mar 16 doi: 10.1016/j.annonc.2021.03.005. PMID: 33741442
Camrelizumab: First Global Approval.
Markham A, Keam SJ
Drugs 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0. PMID: 31313098
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M
Ann Oncol 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199. PMID: 31240302Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Prognosis

Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.
Fichtl A, Seufferlein T, Zizer E
BMC Gastroenterol 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0. PMID: 37986043Free PMC Article
Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS
Med Clin North Am 2023 May;107(3):491-504. Epub 2023 Feb 20 doi: 10.1016/j.mcna.2023.01.002. PMID: 37001949
Liver resection after Transjugular Portosystemic Stent Shunt (TIPSS).
Sliwinski S, Trojan J, Mader C, Vogl T, Bechstein W
Z Gastroenterol 2023 Apr;61(4):390-393. Epub 2022 Jun 13 doi: 10.1055/a-1791-2192. PMID: 35697061
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Midodrine: a novel therapeutic for refractory chylothorax.
Liou DZ, Warren H, Maher DP, Soukiasian HJ, Melo N, Salim A, Ley EJ
Chest 2013 Sep;144(3):1055-1057. doi: 10.1378/chest.12-3081. PMID: 24008957

Clinical prediction guides

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J
Br J Cancer 2024 Feb;130(3):476-482. Epub 2023 Dec 22 doi: 10.1038/s41416-023-02534-1. PMID: 38135713Free PMC Article
Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS
Med Clin North Am 2023 May;107(3):491-504. Epub 2023 Feb 20 doi: 10.1016/j.mcna.2023.01.002. PMID: 37001949
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT
J Clin Oncol 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15 doi: 10.1200/JCO.2017.76.6212. PMID: 30110194Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Minimally invasive esophagectomy for dysplastic Barrett's esophagus.
Markar SR, Hanna G
World J Surg 2015 Mar;39(3):608-14. doi: 10.1007/s00268-014-2746-1. PMID: 25145822

Recent systematic reviews

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E
Oncologist 2021 Oct;26(10):e1704-e1729. Epub 2021 Sep 3 doi: 10.1002/onco.13907. PMID: 34288262Free PMC Article
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A, Park R, Sun W
J Hematol Oncol 2021 Jan 12;14(1):13. doi: 10.1186/s13045-021-01034-0. PMID: 33436042Free PMC Article
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T
Cochrane Database Syst Rev 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2. PMID: 33210731Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...